Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis.

Authors

• Iyad Alnahhas
• Mouaz Alsawas
• Appaji Rayi
• Joshua D Palmer
• Raju Raval
• Shirley Ong
• Pierre Giglio
• Mohammad Hassan Murad
• Vinay Puduvalli

Publication/Presentation Date

1-1-2021

Abstract

[This corrects the article DOI: 10.1093/noajnl/vdaa082.].

Volume

3

Issue

1

First Page

095

Last Page

095

ISSN

2632-2498

Published In/Presented At

Alnahhas, I., Alsawas, M., Rayi, A., Palmer, J. D., Raval, R., Ong, S., Giglio, P., Murad, M. H., & Puduvalli, V. (2021). Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis. Neuro-oncology advances, 3(1), vdab095. https://doi.org/10.1093/noajnl/vdab095

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

34258581

Department(s)

Administration and Leadership

Document Type

Article